Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Details of the presentation are as follows:
- Abstract Number: 241
- Title: Investigation of mRNA Cell Therapy as a Treatment for Autoimmune Disease in Patients with Myasthenia Gravis
- Session Title: Cell Therapy and Cell-Based Gene Therapy Trials
- Session Date/Time: Friday May 10, 2024, 1:30-3:15 p.m. E.T.
- Presentation Time: 1:45-2:00 p.m. E.T.
- Room: Ballroom 1
A copy of the abstract is available through the ASGCT conference website.
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis. Additional Phase 2 studies are planned in systemic lupus erythematosus under an allowed IND, as well as basket trials in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240422345729/en/
Investor Relations:
Melissa Forst
Argot Partners
cartesian@argotpartners.com
Media:
David Rosen
Argot Partners
cartesian@argotpartners.com
Source: Cartesian Therapeutics, Inc.